World of DTC Marketing

JUNE 3, 2022

The continued emphasis on digital health is overrated but digital health will become an integral part of total patient care. To become a vital part of patient care, digital health providers need to provide the medical community with studies that show their value to patient outcomes. Ransomware attacks on hospitals.

Doctors 291

Doctors Insurance Medical Patients 291

European Pharmaceutical Review

OCTOBER 22, 2024

The UK is set to be the first country to introduce a new regulatory framework for innovative products manufactured at or close to the point of patient care, says the Medicines and Healthcare products Regulatory Agency (MHRA). Demand for delivery of care by hospitals will also be eased with implementation of the regulation. [The

Medicine 89

Medicine Manufacturing Safety Consulting 89

MedCity News

JANUARY 30, 2024

By catching the disease early, patients have a higher chance of receiving successful treatment, and the cost of treatment can be significantly reduced. Personalized treatment plans: Treatment plans can vary widely depending on the type of cancer, the stage and the patient’s overall health.

Side effects 325

Side effects Ethics Medical Patients 325

European Pharmaceutical Review

JANUARY 25, 2023

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for exagamglogene autotemcel (exa-cel), the first regulatory submission for a CRISPR-based medicine. The edited cells, exa-cel, are then infused back into the patient as part of an autologous hematopoietic stem cell transplant (HSCT).

Medicine 111

Medicine Food and Drug Administration FDA Pharmaceutical 111

European Pharmaceutical Review

MAY 17, 2024

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorisations for medicines containing 17-hydroxyprogesterone caproate (17-OHPC) in the European Union. Additionally, EMA sought input from experts in obstetrics, gynaecology and fertility treatment, as well as patient representatives.

Medicine 97

Medicine Safety Marketing Medical 97

European Pharmaceutical Review

SEPTEMBER 22, 2022

EBT-101, a CRISPR-Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) has been administered to the first individual in a Phase I/II trial designed to establish its safety and efficacy. As a result, HIV can persist in tissue reservoirs for years.

Patients 145

Patients Safety Medicine Physicians 145

European Pharmaceutical Review

FEBRUARY 4, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for SARCLISA (isatuximab), making it the first and only anti-CD38 quadruplet therapy available for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Food and Drug Administration 80

Food and Drug Administration Medicine Patients Food 80

European Pharmaceutical Review

JULY 12, 2023

Integrated safety analysis from five prospective clinical trials for the first and only single-dose, US Food and Drug Administration (FDA)-approved microbiome -based treatment to prevent recurrent Clostridioides difficile ( C. The analysis is the largest safety evaluation to date of any microbiota-based live biotherapeutic.

Safety 98

Safety Food and Drug Administration Prospecting Food 98

Contrarian Sales Techniques

NOVEMBER 21, 2024

From explaining how a medication works to addressing patient concerns, reps play a vital role in bridging the gap between healthcare providers and patients. The Role of Medical Reps in Patient Education Patient education isn’t just about handing out brochures. What is Evidence-Based Medicine?

Education 52

Education Medical Patients Doctors 52

European Pharmaceutical Review

JANUARY 31, 2023

Dupixent ® is indicated for EoE patients 12 years and older, weighing at least 40kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. All patients had previously not responded to proton pump inhibitors. Improvements were observed as early as four weeks.

Medicine 98

Medicine Safety Patients Pharmaceutical 98

European Pharmaceutical Review

NOVEMBER 10, 2022

A new wave of medicines has emerged in recent years to supplement the well-established small and large molecule platforms that have historically dominated the market. Complex medicines offer diverse therapeutic modalities, including RNA therapeutics and antibody-drug conjugates (ADCs). What constitutes a complex medicine?

Medicine 105

Medicine Distribution Engineering Electronics 105

Pharma Marketing Network

JULY 27, 2022

The patient care team supplies an abundance of information, although sifting through brochures and online resources can be daunting for the patient and their caregiver. 1 The marketer’s goal is to design easy-to-follow patient guidelines while conforming to med-legal language. Meeting Patients Where They Are.

Patients 130

Patients Education Retail Pharma 130

European Pharmaceutical Review

FEBRUARY 5, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) is seeking feedback on its regulatory guidance for individualised mRNA cancer immunotherapies. This guidance aims to streamline access pathways for patients, without compromising on the safety of these personalised immunotherapies.

Food and Drug Administration 52

Food and Drug Administration Government Safety Medicine 52

European Pharmaceutical Review

JULY 3, 2023

Data showed 51 percent of patients on 80mg of the small molecule treatment elafibranor achieved a cholestasis response compared with four percent on placebo. The Phase III trial enrolled 161 patients. A significant proportion of PBC patients are unable to benefit from existing therapies. There are 22.27

Medicine 98

Medicine Food and Drug Administration Food Patients 98

European Pharmaceutical Review

MAY 29, 2024

The safety and tolerability of rationally-designed live bacterial product (LBP) BMC128 combined with nivolumab has shown initial positive trends in non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC), new data from an ongoing Phase I clinical trial suggests.

Patients 98

Patients Safety Medicine Medical 98

European Pharmaceutical Review

OCTOBER 25, 2022

AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) combination therapy has been approved in the US for adult patients with unresectable hepatocellular carcinoma (HCC). Phase III trial results found that three years post-treatment, 31 percent of patients given the drug combination were still alive. p=0.0035).

Food and Drug Administration 111

Food and Drug Administration Patients Safety Physicians 111

European Pharmaceutical Review

OCTOBER 28, 2022

revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. Most mRNA medicines code for natural proteins, although some have been modified. Biotech firm Omega Therapeutics, Inc.

Engineering 111

Engineering Patients Medicine Medical 111

PM360

JUNE 26, 2023

Access to medicines have persisting and systemic differences across the globe and within countries. It is estimated that nearly two billion people globally do not have access to essential medicines. Traditionally, pharmaceutical companies have not prioritized emerging markets as part of their access strategy.

Medicine 98

Medicine Marketing Pharma Manufacturing 98

European Pharmaceutical Review

DECEMBER 18, 2023

After eight weeks of treatment, patients’ depression severity scores dropped by an average of 19.1 A second study led by Yvan Beaussant from the Dana-Farber Cancer Institute that gathered input from patients in the trial during exit interviews. Psychedelic medicines: are they gaining traction in Europe?

Food and Drug Administration 116

Food and Drug Administration Patients Side effects Safety 116

World of DTC Marketing

DECEMBER 23, 2020

According to a study in the Journal for American Board of Family Medicine “respondents (76%) said they were likely to ask a health care provider about advertised drugs; 26% said they had already done so. In an era of a pandemic, are psoriasis patients really going to ask for a drug that may compromise their immune system?

Prescription 249

Prescription Doctors Side effects Marketing 249

Pharma Marketing Network

NOVEMBER 23, 2024

From AI-powered insights to the rise of precision medicine, new trends are reshaping the way we connect with patients and healthcare providers. Whether it’s identifying patient demographics or assessing market needs, research bridges the gap between innovation and engagement.

Marketing 52

Marketing Pharma Ethics Healthcare Provider 52

European Pharmaceutical Review

OCTOBER 20, 2022

City of Hope , one of the largest cancer research and treatment organisations in the US, announced that the first patient to receive novel cancer medicine AOH1996, is doing well. Its objective is to determine the maximum tolerated dose of the investigational pill, AOH1996, and to evaluate the medicine for preliminary efficacy.

Patients 98

Patients Medicine Medical Safety 98

European Pharmaceutical Review

NOVEMBER 17, 2023

During the Phase III clinical trial , patients with migraine who could identify prodromal symptoms that led to headache at least 75 percent of the time. UBRELVY was well-tolerated with no new safety signals observed when administered during the prodrome, data from the clinical trial found.

Medicine 96

Medicine Safety Patients Pharmaceutical 96

pharmaphorum

JANUARY 27, 2023

Having previously spoken with Dr Mullen three years ago when she was country medical director for the UK & Ireland at GSK – on the topic of patient centricity and embedding that focus within the core of a pharmaceutical company – our recent interview provided some interesting insights into the changing landscape of the industry.

Patients 111

Patients Pharmaceutical Medical Physicians 111

European Pharmaceutical Review

JANUARY 17, 2023

A Phase IIa pilot trial of CER-001 showed for the first time in a human pilot trial, that recovery of a normal protein apolipoprotein A-I (apoA-I) level in patients stop the cytokine storm and improve clinical outcomes. CER-001 is the only natural recombinant apoA-I for septic patients at high risk of acute kidney injury (AKI).

Patients 98

Patients Safety Pharma Medicine 98

World of DTC Marketing

JULY 13, 2021

A study published in JAMA Internal Medicine found that among cancer drugs that received accelerated approval from the FDA using surrogate endpoints or other measures, only one-fifth ended up improving overall survival rates in later confirmatory trials. The issue continues to be “do patients, and caregivers understand the risk?”

FDA 187

FDA Medicine Healthcare Healthcare 187

Infuse Medical

FEBRUARY 4, 2025

This creates a gap in knowledge that impacts patient outcomes and organizational efficiency. Inadequate training can result in increased procedural errors, slower adoption of new technologies, and compromised patient safety. Global Scalability and Consistency Technology-driven training solutions offer unparalleled scalability.

Training 130

Training Medical Healthcare Healthcare 130

European Pharmaceutical Review

DECEMBER 7, 2022

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Comirnaty ® , the Pfizer/BioNTech COVID-19 vaccine for infants and children aged six months to four years in Great Britain. Additional authorisations and recommendations of Comirnaty ®.

Food and Drug Administration 98

Food and Drug Administration Patients Side effects Medicine 98

European Pharmaceutical Review

FEBRUARY 27, 2024

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. While she is stepping down from her current role, Dame June shared that she still hopes to contribute “to patient safety and public health in other ways.”

Safety 111

Safety Pharmacology Medicine Management 111

pharmaphorum

DECEMBER 1, 2022

Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials. A 2018 NIH survey found that patients felt clinical trial participation to be inconvenient and burdensome, and nearly half (49.0%) said it disrupted their daily routine.

Patients 111

Patients Transportation Retail Recruitment 111

European Pharmaceutical Review

JUNE 13, 2024

Shortly thereafter, the European Medicines Agency (EMA) reviewed the study design, endpoints, and planned statistical analysis, and deemed the US-based trial acceptable for a Marketing Authorisation Application (MAA). In December 2023, the FDA granted OCU400 Regenerative Medicine Advanced Therapy (RMAT) designation.

Manufacturing 145

Manufacturing Food and Drug Administration Engineering Safety 145

Healthcare Success

MAY 9, 2022

The QR code allows hospitals and healthcare providers to satisfy this need with immediate physician-patient interaction and engagement – all through smartphones and tablets. . In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. .

Leads 109

Leads Patients Healthcare Provider Healthcare 109

European Pharmaceutical Review

MAY 2, 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). According to the MHRA, artificial intelligence offers “improved efficiencies”, enabling patients in the UK to safely access medical products earlier.

Safety 115

Safety Medicine Government Medical 115

European Pharmaceutical Review

JANUARY 23, 2025

US researchers have shown that the Factor XI inhibitor abelacimab significantly reduced bleeding in patients with atrial fibrillation compared to a standard-of-care anticoagulant, rivaroxaban. This bleeding is most common type observed in patients taking anticoagulants, the researchers highlighted.

Safety 52

Safety Patients Medical Medicine 52

European Pharmaceutical Review

NOVEMBER 28, 2024

This dual-layer certification process can create significant delays, as each framework involves extensive assessments for safety and performance under separate requirements specific to medical device and AI-specific criteria. If successful in other jurisdictions, such product will eventually make their way to Europe for approval.

Government 105

Government Medical Safety Management 105

Contrarian Sales Techniques

NOVEMBER 18, 2024

Have you ever gone to a pharmacy with a prescription, only to find out the medicine isn’t in stock? When a pharmacist recommends an alternative, they’re using their expertise to find a medicine that works the same way as the one you were prescribed. Pharmacists are often the bridge between our products and the patients who need them.

Medicine 52

Medicine Prescription Training Sales 52

European Pharmaceutical Review

NOVEMBER 16, 2023

It has been conditionally authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a gene-editing therapy for certain patients 12 years old and over with sickle-cell disease and transfusion-dependent β-thalassemia. No significant safety concerns were identified during the trials.

Safety 114

Safety Side effects Patients Medicine 114